These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1061 related articles for article (PubMed ID: 30853353)

  • 1. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.
    Jiang YZ; Ma D; Suo C; Shi J; Xue M; Hu X; Xiao Y; Yu KD; Liu YR; Yu Y; Zheng Y; Li X; Zhang C; Hu P; Zhang J; Hua Q; Zhang J; Hou W; Ren L; Bao D; Li B; Yang J; Yao L; Zuo WJ; Zhao S; Gong Y; Ren YX; Zhao YX; Yang YS; Niu Z; Cao ZG; Stover DG; Verschraegen C; Kaklamani V; Daemen A; Benson JR; Takabe K; Bai F; Li DQ; Wang P; Shi L; Huang W; Shao ZM
    Cancer Cell; 2019 Mar; 35(3):428-440.e5. PubMed ID: 30853353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer.
    Li RQ; Yan L; Zhang L; Ma HX; Wang HW; Bu P; Xi YF; Lian J
    Sci Rep; 2024 May; 14(1):12386. PubMed ID: 38811720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
    Bareche Y; Venet D; Ignatiadis M; Aftimos P; Piccart M; Rothe F; Sotiriou C
    Ann Oncol; 2018 Apr; 29(4):895-902. PubMed ID: 29365031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.
    Liu YR; Jiang YZ; Xu XE; Yu KD; Jin X; Hu X; Zuo WJ; Hao S; Wu J; Liu GY; Di GH; Li DQ; He XH; Hu WG; Shao ZM
    Breast Cancer Res; 2016 Mar; 18(1):33. PubMed ID: 26975198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
    Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
    Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.
    Barrett MT; Lenkiewicz E; Malasi S; Basu A; Yearley JH; Annamalai L; McCullough AE; Kosiorek HE; Narang P; Wilson Sayres MA; Chen M; Anderson KS; Pockaj BA
    Breast Cancer Res; 2018 Jul; 20(1):71. PubMed ID: 29996881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
    Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
    Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer.
    Chen SH; Tse KP; Lu YJ; Chen SJ; Tian YF; Tan KT; Li CF
    Cancer Med; 2024 Jun; 13(12):e7384. PubMed ID: 38895905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification.
    Lee M; Yoo TK; Chae BJ; Lee A; Cha YJ; Lee J; Ahn SG; Kang J
    Sci Rep; 2024 May; 14(1):11278. PubMed ID: 38760384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer.
    Kumar S; Bal A; Das A; Loriya I; Khare S; Bhattacharya S; Singh G
    Breast Cancer Res Treat; 2021 Jun; 187(3):625-633. PubMed ID: 33954864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
    Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
    Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
    Burstein MD; Tsimelzon A; Poage GM; Covington KR; Contreras A; Fuqua SA; Savage MI; Osborne CK; Hilsenbeck SG; Chang JC; Mills GB; Lau CC; Brown PH
    Clin Cancer Res; 2015 Apr; 21(7):1688-98. PubMed ID: 25208879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication.
    Lee YM; Oh MH; Go JH; Han K; Choi SY
    Genes Genomics; 2020 Dec; 42(12):1381-1387. PubMed ID: 33145728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes.
    Elfgen C; Reeve K; Moskovszky L; Güth U; Bjelic-Radisic V; Fleisch M; Tausch C; Varga Z
    J Cancer Res Clin Oncol; 2019 Aug; 145(8):2051-2059. PubMed ID: 31270600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
    Karn T; Jiang T; Hatzis C; Sänger N; El-Balat A; Rody A; Holtrich U; Becker S; Bianchini G; Pusztai L
    JAMA Oncol; 2017 Dec; 3(12):1707-1711. PubMed ID: 28750120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
    Ma D; Jiang YZ; Xiao Y; Xie MD; Zhao S; Jin X; Xu XE; Shao ZM
    Cancer; 2020 Jul; 126(14):3209-3218. PubMed ID: 32383785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic landscape of breast cancer and mutation tracking with circulating tumor DNA in Chinese women.
    Wang Y; Lin L; Li L; Wen J; Chi Y; Hao R; Dai X; Chen Y; Huang D; Zhou Y; You J; Ye Z; Chen H; Jin L; Chen D; Yang F; Xia E; Ma X; Guo F; Tong Y; Zheng M; Wang O
    Aging (Albany NY); 2021 Apr; 13(8):11860-11876. PubMed ID: 33893247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer.
    Xiao Y; Ma D; Yang YS; Yang F; Ding JH; Gong Y; Jiang L; Ge LP; Wu SY; Yu Q; Zhang Q; Bertucci F; Sun Q; Hu X; Li DQ; Shao ZM; Jiang YZ
    Cell Res; 2022 May; 32(5):477-490. PubMed ID: 35105939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in molecular features of triple-negative breast cancers based on the age at diagnosis.
    Gulbahce HE; Bernard PS; Weltzien EK; Factor RE; Kushi LH; Caan BJ; Sweeney C
    Cancer; 2018 Dec; 124(24):4676-4684. PubMed ID: 30311638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDKN2A loss and PIK3CA mutation in myoepithelial-like metaplastic breast cancer.
    Bartels S; van Luttikhuizen JL; Christgen M; Mägel L; Luft A; Hänzelmann S; Lehmann U; Schlegelberger B; Leo F; Steinemann D; Kreipe H
    J Pathol; 2018 Jul; 245(3):373-383. PubMed ID: 29708279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.